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Summary
 
Superantigens are defined as proteins that activate a large number of T cells through interaction
with the V
 
b
 
 region of the T cell antigen receptor (TCR). Here we demonstrate that the super-
antigen produced by 
 
Mycoplasma arthritidis
 
 (MAM), unlike six bacterial superantigens tested, in-
teracts not only with the V
 
b
 
 region but also with the CDR3 (third complementarity-deter-
mining region) of TCR-
 
b
 
. Although MAM shares typical features with other superantigens,
direct interaction with CDR3-
 
b
 
 is a feature of nominal peptide antigens situated in the antigen
groove of major histocompatibility complex (MHC) molecules rather than superantigens. Dur-
ing peptide recognition, V
 
b
 
 and V
 
a
 
 domains of the TCR form contacts with MHC and the
complex is stabilized by CDR3–peptide interactions. Similarly, recognition of MAM is V
 
b
 
-
dependent and is apparently stabilized by direct contacts with the CDR3-
 
b
 
 region. Thus,
MAM represents a new type of ligand for TCR, distinct from both conventional peptide anti-
gens and other known superantigens.
 
I
 
n the first step of a specific immune response, T lympho-
cytes are activated by interaction between the TCR and
peptide antigen bound to the MHC. Specific peptide rec-
ognition is achieved by the unique structure of TCRs,
formed by somatic rearrangement of their composite gene
segments (V
 
a
 
, J
 
a
 
, V
 
b
 
, D
 
b
 
, and J
 
b
 
). Most contacts with
peptide are formed by very diverse CDR3 (third comple-
mentarity-determining region) regions that are encoded by
the V-D-J junctional region (1, 2). During recombination,
a second level of diversity is provided by the trimming and
addition of nucleotides (N-additions)
 
1
 
 at the junctions (3).
As a result of the huge diversity of TCRs created, one pep-
tide antigen activates only a small number of T cells bearing
specific receptors. However, several groups of microorgan-
isms have developed a way to activate large numbers of T
cells. They produce superantigens, potent stimulators of T
cells, that form contacts with lateral surfaces of both the
MHC and TCR. In superantigen recognition, the com-
plexity of the TCR is ignored and interaction occurs be-
tween the V
 
b
 
 region and the superantigen. In this way, a
single superantigen can activate 
 
.
 
10% of all T cells (4–6).
Superantigens can be produced by bacteria, viruses, and
even plants (7–9). Their biological role remains unclear,
except for several mouse mammary tumor virus (MMTV)
superantigens that are essential during the viral life cycle.
By activating T and B cells in neonatal mice, MMTV su-
perantigens form a pool of dividing cells that amplify the
viral load and allow viral persistance until maturation of the
main target site, the mammary tissue. The endogenous
form of MMTV superantigen, acquired by integration of
the viral gene into the mouse genome, has the opposite
role. Mice expressing endogenous superantigens are pro-
tected from viral infection because of deletion of the super-
antigen-reactive T cell V
 
b
 
 subsets in early development
(10, 11). Other superantigens also cause proliferation and
expansion of T cells with a responding V
 
b
 
 phenotype, of-
ten followed by deletion of the targeted subset. It has been
hypothesized that nonspecific stimulation of large numbers
of T cells by superantigens could include self-reactive T
cells and lead to autoimmunity (5). A recent report suggests
involvement of a human endogenous retrovirus (HERV-K)–
encoded superantigen in induction of autoimmune diabetes
(12). Unlike MMTV-encoded superantigens that are prod-
ucts of the 3
 
9
 
 LTR, this superantigen seems to be encoded
by the 
 
env
 
 gene. It activates the V
 
b
 
7
 
1
 
 subset of T cells,
which was previously found to be enriched in pancreatic
infiltrates of diabetic patients (13).
 
1
 
Abbreviations used in this paper:
 
 MAM, 
 
Mycoplasma arthritidis
 
 mitogen;
MMTV, mouse mammary tumor virus; SE, staphylococcal enterotoxin.
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CDR3-dependent Superantigen
 
The superantigen produced by 
 
Mycoplasma arthritides
 
(MAM) does not have significant homology to the primary
sequence of other known bacterial or viral superantigens
(14). Nevertheless, MAM shares several features common
to many superantigens, including requisite presentation by
MHC class II to responding CD4 and CD8 T cells, lack of
restriction of the presenting MHC class II alleles, lack of an
antigen processing requirement, and the ability to stimulate
T cells expressing specific V
 
b
 
 genes (for review see refer-
ence 15). However, functional differences between MAM
and other superantigens have been noted. MAM is a rela-
tively weak mitogen for polyclonal human T cells, but it is
an efficient stimulator of B cells and induces IgM produc-
tion better than do staphylococcal superantigens (16). It has
been suggested that the poor mitogenic activity of MAM
reflects a lower frequency of MAM-reactive T cells among
peripheral lymphocytes compared with other superantigens
(16, 17).
Here we demonstrate that the MAM represents a new
type of ligand for the TCR, intermediate between super-
antigens and conventional peptide antigens, because it
forms contacts both within the V
 
b
 
 region and the CDR3-
 
b
 
region of the TCR.
 
Materials and Methods
 
Human T Cell Clones.
 
CD4
 
1
 
 clones were obtained after
stimulation of fresh PBL with MAM by limiting dilution in 96-
well plates. Every 2 wk clones were stimulated by sodium perio-
date–treated non-T PBL as previously described (18) and main-
tained in RPMI 1640 with 10% FCS and 5% IL-2 (Pharmacia
Biotech, Piscataway, NJ).
 
Proliferative Response.
 
2 
 
3
 
 10
 
4
 
 T cells and 1.5 
 
3
 
 10
 
4
 
 irradiated
(15,000 rads) lymphoblastoid 8866P cells were incubated with
10-fold dilutions of superantigens (from 1 to 10
 
2
 
5
 
 ng/ml) in trip-
licate microwells for 48 h, then labeled overnight with [
 
3
 
H]-thy-
midine and harvested. Reactivity was scored as cpm greater than
twofold over background. Superantigens were purchased from Toxin
Technology, (Sarasota, FL); MAM, purified to homogeneity, was
provided by Dr. B.C. Cole (University of Utah School of Medi-
cine, Salt Lake City, UT) and prepared according to reference 19.
 
TCR Sequencing.
 
cDNAs obtained from human T cell clones
were amplified with primers specific for human V
 
b
 
 families (18)
and V
 
a
 
 families (20), cloned into a pCRII vector (Invitrogen
Corp., Carlsbad, CA) and sequenced by the Sequenase 2 method
(United States Biochemical, Cleveland, OH). Expression of V
 
b
 
5.1, V
 
b
 
 8.1/2, V
 
b
 
12.2, and V
 
b
 
17.1 was confirmed by staining
with anti-V
 
b
 
–specific monoclonal antibodies (21).
 
Transfection of TCR 
 
b
 
 Chains.
 
The retroviral cassette pTbeta
was constructed by subcloning a SnabI-SalI fragment of mouse
C
 
b
 
2 gene into the pBabe Puro vector (22). PCR products con-
taining the leader sequence, V
 
b
 
 region, N, D
 
b
 
, and J
 
b
 
 were de-
rived from T cell clones N17 and J17. Mutants were generated by
overlapping extension PCR (23) cloned into pTbeta and trans-
fected into the packaging cell line BOSC by the calcium phos-
phate method (24). TCR 
 
b
 
 chain–deficient T hybridoma cell
lines DS 23.27 (mouse V
 
a
 
2; reference 25) and YL
 
b
 
- (mouse
V
 
a
 
3.1; reference 26) were infected with each virus, puromycin-
selected, and sorted for V
 
b
 
17 expression using the C1 mono-
clonal antibody (21).
 
IL-2 Production Assay.
 
Activation of the TCR transfectants
was tested according to reference 27. 10
 
5
 
 cells in a 100 
 
m
 
l/well
were mixed with an equal number of 8866P lymphoblastoid cells.
10-fold dilutions of each superantigen were tested in triplicates.
After 24 h, supernatants were frozen at 
 
2
 
20
 
8
 
C. Portions of these su-
pernatants were thawed and incubated for 24–30 h with IL-2–
dependent HT-2 cells at 4,000 cells/well. Viability of HT-2 cells
was evaluated by the MTT (3-(dimethylthiazol-2-yl)-2,5-diphe-
nyl tetrazolium bromide) assay and analyzed on an ELISA reader
at 570 nm (28). The amount of IL-2 produced was determined in
comparison with the standard curve established with recombinant
IL-2 (BRMP units; Becton Dickinson).
 
Results
 
MAM Reactivity Is Not Determined by TCR V
 
b
 
 Alone.
 
To characterize MAM-reactive TCRs, we tested a panel of
16 human T cell clones for proliferative responses to 7 dif-
ferent superantigens (Table 1, Fig. 1). Clonal T cells were
incubated with APCs in the presence of gradual 10-fold di-
lutions of each superantigen, then pulsed with [
 
3
 
H]-thymi-
dine and harvested. Among T cell clones using the same
V
 
b
 
 genes, similar patterns of reactivity were observed with
most superantigens, whereas reactivity to MAM often dif-
fered (Fig. 1, 
 
shaded field
 
). T cell clones expressing either
V
 
b
 
5.1, V
 
b
 
8, V
 
b
 
12, or V
 
b
 
17 could respond to MAM, but
within each of these V
 
b
 
 subsets there were both reactive
 
Table 1.
 
Proliferative Response of Two V
 
b
 
17
 
1
 
 Clones to
Several Superantigens
 
Concentration
10
 
2
 
1
 
10
 
2
 
2
 
10
 
2
 
3
 
10
 
2
 
4
 
ng/ml
 
Clone N17 (V
 
b
 
17.1)
 
*
 
SEB 28,261 19,957 11,042 6,378
SEE 1,480 1,128 1,189 1,189
TSST 2,110 1,921 1,731 1,110
MAM 13,043 16,165 10,888 3,891
SEC1 13,870 19,182 13,218 9,241
SEC2 16,884 16,204 12,381 11,922
SEC3 16,048 18,197 13,877 8,039
Clone J17 (V
 
b
 
 17.1)
 
‡
 
SEB 23,107 20,380 19,807 2,687
SEE 555 424 493 420
TSST 578 611 576 432
MAM 496 455 496 480
SEC1 15,534 17,898 15,191 6,453
SEC2 12,958 15,322 12,419 4,035
SEC3 15,957 20,429 14,608 2,038
 
*
 
Background: 1,239 CPM
 
‡
 
Background: 394 CPM
Numbers show mean CPM of triplicates. Each T cell clone was tested
at least four times. Data on 16 clones are summarized in Figure 1. 
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(MAM
 
1
 
) and nonreactive (MAM
 
2
 
) clones. Lack of reac-
tivity to MAM was not dose dependent, as we were unable
to find concentrations of MAM that would activate MAM
 
2
 
clones (Table 1). The MAM
 
2
 
 cells were competent to re-
spond to TCR-mediated signals from other superantigens
(Fig. 1). In addition, the sequences of TCR V
 
b
 
 regions from
MAM
 
1
 
 and MAM
 
2
 
 T cell clones were identical, ruling
out the possibility that V
 
b
 
 allelic variants resulted in differ-
ences in MAM reactivity.
Strikingly, all T cell clones that did not respond to MAM
used the TCR J
 
b
 
2.1 gene segment, whereas MAM-reac-
tive clones used other J
 
b
 
2 segments (Fig. 2). Alignment of
the CDR3 regions showed that a tyrosine (Y), present
within the conserved motif Q(Y/F)FG, correlated with re-
sponsiveness to MAM. Nonreactive clones had phenylala-
nine (F) at this position. The same correlation was observed
in polyclonal cell lines obtained after repeated stimulation
of fresh T cells with MAM. Dominant clones within these
cultures (Fig. 2; 
 
SEL
 
) represent T cells expanded in vitro
after stimulation with MAM. All V
 
b
 
17 MAM1 and SEL
clones have isoleucine at position 94 in addition to Y
within the Q(Y/F)FG motif in their CDR3-b region.
Staining data indicated that in the polyclonal cell lines
only the Vb171 subset was expanded in response to MAM,
to z50% of all T cells, in agreement with previous data
(21). The minor MAM-responsive phenotypes (Vb5, Vb8,
and Vb12) were not expanded in these polyclonal cell
lines. However, within these minor Vb subsets, dominant
clones were also found after three to five stimulations with
MAM. We hypothesize that these clones represented rela-
tively infrequent cells within the Vb5, Vb8, or Vb12 sub-
sets, which may depend on the other TCR elements for
Figure 2. TCR a and b
chains from human T cell clones
with different MAM reactivity.
The sequences represent MAM-
reactive clones (1), MAM non-
reactive clones (2), and domi-
nant clonal sequences (SEL) ob-
tained from three polyclonal cell
lines (K3, J5, D3) that were re-
peatedly stimulated with MAM,
respectively, 33, 53, or 33 con-
secutively at 2-wk invervals. The
ratio shown after the name of the
cell line indicates the number of
identical CDR3-b sequences over
the total number of sequences
obtained for the indicated Vb
subset. Va and Vb nomenclature
is according to reference 63, and Ja
is according to EMBL/Genbank/
DDBJ accession No. M94081.
Figure 1. Proliferative response of human T cell clones to bacterial su-
perantigens. The shaded boxes represent examples of clones differing in
MAM reactivity despite shared Vb usage (Vb5.1, 8, 12.2 and 17.1).
Vb13.1 and 13.2 differ primarily in the HVR4 region, a component of
the lateral TCR surface that interacts with superantigens (24, 37). We
confirm that TCRs expressing the two closely related Vb13 gene seg-
ments have few superantigen reactivities in common. Key to symbols: 2,
no reactivity with 1 ng/ml or any concentration; 1, reactivity with 1021
ng/ml or greater; 11, reactivity with 1022 ng/ml or greater; 111, re-
activity with 1023 ng/ml or greater. See Table 1 for example of raw data.322 CDR3-dependent Superantigen
MAM reactivity. Consistent with this view, Va2 and Va8
were frequently observed in clones of minor Vb pheno-
types (Fig. 2). Thus, reactivity may depend on Va usage
with these minor Vb phenotypes, as previously described
for low affinity TCR Vb–superantigen interactions (29–31).
However, the major MAM-responsive Vb17 phenotype
is not a chain–dependent. To prove this point, we trans-
fected b chains derived from clones N17 and J17 into two
mouse T hybridoma cell lines, DS 23.27 and YLb-, that
are b chain–deficient (Table 2). Surface expression of the
endogenous mouse TCR-a chain, either Va2 or Va3.1,
respectively, is rescued by TCR complex formation with
the transfected b chain. b chains N17 and J17 retained
their differential MAM reactivity regardless of which a
chain they were paired with (Table 2).
Presentation of superantigens to T cell clones can be sen-
sitive to minor differences among MHC class II alleles (32)
and the nature of the peptide in the MHC class II groove
(33). Therefore, we tested the reactivity of MAM1 and
MAM2 clones with three superantigens presented by lym-
phoblastoid cell lines expressing different MHC class II al-
leles (Fig. 3). In each of four groups (Vb17, Vb8, Vb12,
and Vb5), MAM1 and MAM2 clones retained their spe-
cific reactivity regardless of the MHC class II alleles ex-
pressed on APCs. The magnitude of the proliferative re-
sponses differed from one APC type to another, probably
due to different levels of expression of MHC class II or ac-
cessory molecules, but the pattern of reactivity remained
the same. MAM1 clones were always MAM-reactive and
MAM2 clones did not respond to MAM presented by
other APCs.
TCR-b Chain CDR3 Mutants. Sequence alignment of
TCR-b chains implicated a single residue (Y/F) of the
CDR3 region in determining MAM reactivity (Fig. 2). To
test whether Y103 of clone N17 (MAM1) and the equiva-
lent residue, F106, of clone J17 (MAM2) determine MAM
reactivity, we attempted to reconstitute reactivity of J17 by
mutagenesis in the CDR3-b region (Fig. 4). Wild-type
and mutant TCRs were expressed in DS23.27 cells and
tested for IL-2 production in response to several superanti-
gens. A single amino acid substitution (JY, F106Y) at posi-
tion 106 was insufficient to restore reactivity to MAM. A
second candidate amino acid was isoleucine in position 94.
This position is encoded by the Vb–Db junctional region
and in all Vb171 clones reactive with MAM, it was repre-
sented by isoleucine (Fig. 2). Therefore, we introduced a
second substitution at position D94 of J17. Strikingly, the
combination of D94I and F106Y (transfectant JIY) resulted
in full reconstitution of MAM reactivity (Fig. 4) while the
single change, D94I, was insufficient (JIF).
To demonstrate that other regions of CDR3 were not
involved, we tested three deletion mutants including either
Table 2. TCR a chain Does Not Contribute to the Recognition of MAM by Vb171 TCRs
N17 J17 Recipient cell line
10 ng/ml 1 ng/ml 0.1 ng/ml 10 ng/ml 1 ng/ml 0.1 ng/ml
SEC2 605 465 216 823 784 167 DS 23.27
MAM 559 604 452 0 0 0 DS 23.27
SEC2 550 414 67 590 502 126 YLb-
MAM 362 334 43 0 0 0 YLb-
Numbers indicate IL-2 U/ml produced after stimulation of transfectants with superantigens. Two TCR b chains derived from clones N17 (MAM1) 
and J17 (MAM2) were expressed in mouse T hybridomas deficient for TCR b chain (DS 23.27, with endogenous mouse Va2; or YLb-, with en-
dogenous mouse Va3.1). Resulting transfectants expressed functional TCRs formed by coupling of their endogenous TCR a chains with N17 or 
J17 b chains. TCR b chains N17 and J17 remained MAM1 and MAM2, respectively, when paired with the same TCR a chain (either DS or YL).
Figure 3. Reactivity to MAM is not MHC-restricted. Four lympho-
blastoid cell lines, 2P68 (HLA DR4), LS (HLA DR5,2), RF (HLA
DR2,6), and 8866P (HLA DR15), were used for presentation of MAM,
SEC2, and SEE to MAM1 and MAM2 T cell clones. In each group of T
cell clones (Vb17, Vb8, Vb12, and Vb5) specific reactivity with the
tested superantigens was not dependent on the HLA alleles expressed.
MAM1 clones remained reactive regardless of the APCs used and MAM2
clones remained nonreactive.323 Hodtsev et al.
one or two residues between I94 and Y106 (JIY-SY, JIY-
NE, JIY-E). These mutants would be expected to differ in
their peptide/MHC reactivity, because recognition of con-
ventional peptide antigen is extremely sensitive to changes
in CDR3 (34, 35). All three deletion mutants retained
MAM reactivity (Fig. 4). Together with the data on MAM
presentation by different MHC class II alleles (Fig. 3) these
experiments exclude a role for MHC II–bound peptides in
these MAM–TCR interactions. A direct contact between
TCR CDR3-b and MAM is the most likely explanation
for dependence on residues I94 and Y106. Based on recent
crystallographic data, these two amino acids are located at
the base of the CDR3 loop lying in close proximity to one
another (36). The side chain of Y106 extends towards the
exposed surface of the TCR (Y107 in reference 2). It ap-
pears that residues I94 and Y106 are accessible for direct in-
teraction with MAM. These interactions are specific for
MAM since none of the tested mutations affected reactivity
with staphylococcal superantigens (Fig. 4).
Discussion
CDR3-dependent Superantigen. In this study we show
that the CDR3 region of TCR-b chain mediates specific
recognition of the MAM superantigen. Complementarity-
determining regions (CDR loops) (2, 37) represent hyper-
variable loops of the TCR that face the MHC during anti-
gen recognition. On the b chain, both CDR1 and CDR2
as well as the HVR4 loops can be involved in interactions
with superantigens. TCR-b point mutations that affect
specific interaction with a particular superantigen are shown
in Fig. 5. The cocrystals of TCR b chain with staphylococcal
enterotoxins SEC2 and SEC3 revealed that these staphylo-
coccal superantigens interact with CDR1, CDR2, FR3,
and HVR4 but not with the CDR3 loop (38). Most con-
tacts (47%) are formed between the superantigen and the
CDR2 loop. Since Y106 of CDR3 (2) and exposed CDR2
residues are located at opposing faces of the TCR b chain
(1), our data suggest that recognition of MAM and staphy-
lococcal superantigens is substantially different. That CDR2
Figure 4. Mapping of the TCR
residues required for reactivity
with MAM. Mutations based on
alignment between N17 and J17
map the positions involved in in-
teraction with MAM (I and Y).
Deletions in the middle of the
CDR3 loop (D) did not affect
reactivity, as well as several mu-
tations in the HVR4 region.
Constructs marked with a * were
transfected into both DS23.27
(mouse Va2) and YLb- (mouse
Va3) cells, and had identical re-
activity regardless of the a chain
used. 10-fold dilutions of super-
antigens were tested in IL-2 as-
says as described in reference 26,
(see also Table 2). Reactivity was
scored as the minimal concentra-
tion of the tested superantigens
required for an IL-2 response
and the key to the symbols is:
111, 0.1 ng/ml, 11, 1 ng/ml,
and 1, 10 ng/ml.
Figure 5. Linear model of
TCR-b indicating residues im-
plicated as superantigen (SAG)
interaction sites by mutation stud-
ies. Typically, superantigens in-
teract with solvent-exposed resi-
dues of CDR1, CDR2, and
HVR4  encoded by Vb genes (24,
64-67). The interaction of MAM
with TCR-b is clearly distinct, as
it interacts both with the Vb re-
gion because of its Vb specificity
(the exact site is not known), and
with two residues located at the
base of the CDR3-b loop.324 CDR3-dependent Superantigen
regions are not involved in MAM recognition is supported
by the observation that the primary sequence of the ho-
mologous human Vb17 and mouse Vb6 chains, both
MAM-reactive, differs in the CDR2 region.
Mutational and structural studies have shown that the
CDR3 loops of the a and b chains are central in peptide
recognition (1, 2, 34, 35, 39, 40). CDR3 regions are the
most diverse parts of the TCR produced by extensive pro-
cessing of end joints during antigen receptor rearrangement
(3). Junctional diversity is increased by N-additions con-
tributed by the lymphoid-specific enzyme terminal deoxy-
transferase (TdT; references 41–43). Although an N-region–
depleted TCR repertoire from TdT-knockout mice was
shown to be as efficient as normal TCR repertoire (44), the
N-region-depleted TCRs were more promiscuous in pep-
tide recognition. These TCRs recognized a significantly
larger number of different peptides than did the wild-type
TCRs when tested for reactivity against a library of random
peptides (45).
The structural basis for the role of N-encoded TCR res-
idues was revealed in a recently solved structure of the
TCR–MHC interface (1). In this crystal, three interactions
are formed between residue p5 of the peptide and the
TCR. Two of these are contacts of p5 with N-encoded
residues of the Va–Da and Vb–Db junctional regions.
The specific interaction of MAM with the TCR appears
to imitate the natural process of peptide/MHC recogni-
tion. During peptide recognition, CDR3 regions of a and
b chains form contacts with MHC. The complex is stabi-
lized by CDR3–peptide interactions (46, 47). Recognition
of MAM is clearly Vb-dependent, as is the case with other
superantigens, but it appears to be stabilized by additional
contacts with the CDR3-b region.
In all MAM-reactive Vb171 clones that we have se-
quenced, position 94 was represented by isoleucine. I94 is
adjacent to the conserved end of Vb region CASS and cor-
responds to position 2 of the CDR3 region (48, 49). In
random CDR3 sequences, position 2 is rarely represented
by isoleucine (49) but in Vb171 sequences I94 is more
common, occurring in z20% of the sequences (50). This
residue is often assumed to be part of the N-region, but in
the case of isoleucine it may be encoded by the 39 end of
the germline Vb17 sequence, codon ATA of the genomic
sequence (51). However, in z80% of the cases this codon
is removed during Vb–Db recombination and replaced by
N-additions.
The second CDR3-b position critical for interaction
with MAM is tyrosine within the Q(Y/F)FG motif of Jb2
(T cell clones using Jb1 are rare and they were not analyzed
in this study). At this position Y is encoded by Jb2.3,
Jb2.4, Jb2.5, and Jb2.7. F, which does not allow MAM re-
activity (Fig. 4), is encoded by Jb2.1 and Jb2.2. The Jb2.1
segment, which was used by the MAM2 T cell clones stud-
ied here (Fig. 2), is used by z40% of all T cells from pe-
ripheral blood (52).
The major subset of T cells targeted by MAM is the
Vb17 subset (21). Yet not all Vb171 T cells respond to
MAM, and the response is limited to cells expressing two
appropriate residues at the base of the CDR3-b loop. This
suggests that T cell activation by MAM is dependent on
TCR junctional diversity, thus limiting the number of po-
tential MAM-reactive T cell clones. The frequency of T
cells responding to this superantigen could be significantly
lower than to other superantigens (for example SEB,
SEC1, SEC2, and SEC3). Among the minor MAM-
responsive TCR phenotypes (Vb5, Vb8, and Vb12), the
frequency is even lower than within the Vb17 subset,
probably because Va usage is an additional requirement as
suggested by the data in Fig. 2. As previously shown,
MAM-responsive T cells expressing Vb5, Vb8, and Vb12
can only be detected by testing individual clones and these
Vb phenotypes do not expand in polyclonal cultures ex-
posed to MAM (18). However, TCRs of the minor phe-
notype also appear to use the Jb-encoded tyrosine for
MAM recognition (Fig. 2).
It is possible that Jb usage can affect low affinity interac-
tions of TCR with other superantigens. Incomplete dele-
tion of Vb81 or Vb61 cells in mice carrying Mls-1a (Mtv-7)
revealed that TCRs that escaped deletion used distinct Jb
regions (53, 54). In this experimental system, Jb1.2 seemed
to protect Vb61 TCR from interaction with a retroviral
superantigen, Mls-1a. However, these studies did not find
any conserved motifs in the CDR3 region that could be
implicated in unresponsiveness to Mls-1a (54). Staphylo-
coccal superantigens seem to be CDR3-independent (Fig.
4 and reference 55). However, in the case of SEB and Ur-
tica dioica superantigens, it was suggested that the Jb seg-
ment, but not the CDR3 region, can affect superantigen
binding by influencing the quaternary structure of the
TCR-b chain (55).
The major MAM-responsive Vb phenotype is strikingly
dependent on discrete residues of CDR3. This fact clearly
distinguishes MAM from other superantigens. Thus, recog-
nition of MAM is dependent on junctional diversity of the
TCR b chain.
Autoimmunity. Mycoplasma arthritides is a microorganism
that causes a disease in rodents that is remarkably similar to
human rheumatoid arthritis (RA). It is also the only myco-
plasma that produces MAM. It should be emphasized that
Mycoplasma arthritides is not a human pathogen. Surpris-
ingly, preferentially expanded T cell clonotypes found in
human RA often belong to the MAM-reactive TCR phe-
notype. Dominant clones from RA patients, characterized
in three independent studies, were found to use Vb17 fol-
lowed by isoleucine at position 94 (50, 56, 57). In one of
the studies, these T cells were shown to be autoreactive
against a lymphoblastoid cell line expressing HLA-DR4
(50). Similar autoreactivity was reported in a TCR trans-
genic mouse model of RA (58). Inflammatory sinovitis in
mice was triggered by the transgenic TCR recognition of
host MHC class II (Ag7). This transgenic TCR-b chain
used a mVb6 followed by isoleucine (CASSI) (D. Mathis,
personal communication). Murine Vb6 is the closest ho-
mologue of human Vb17, and mouse Vb61 T cells are also
MAM-reactive (15). Thus, both murine and human TCRs
associated with RA appear to express a conserved isoleu-325 Hodtsev et al.
cine at the COOH-terminal end of the Vb region. The
role of the conserved isoleucine in the CDR3-b region of
arthritogenic TCRs remains to be determined. Is it neces-
sary for interaction with MHC class II or a putative joint-
specific peptide? Is it possible that tolerized self-reactive
clones can be reactivated by MAM in mice infected by My-
coplasma arthritides?
There is a strong genetic link between certain DR alleles
(class II MHC) and RA in humans (59, 60). Position 71 of
the particular DR4 or DR1 b chains, a lysine residue, is as-
sociated with susceptibility for RA (61). This residue deter-
mines the nature of the peptides in the class II groove by
interacting with P4/P5 of the peptide (for review see refer-
ence 62). Conserved CDR3-b motifs that include isoleu-
cine 94 have been proposed as evidence for antigen-driven
immune response in RA (50). Whether superantigens like
MAM have a role in RA pathogenesis is still an open ques-
tion.
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